A Clinical Monitoring Program of COVID-19 Outpatients: A Prospective Cohort Study
Purpose. Coronavirus disease 2019 (COVID-19) has been associated with a high rate of mortality and morbidity. While a high portion of COVID-19 patients have mild symptoms, a limited number of clinical trials have evaluated the clinical course of this large group of patients. This study was designed...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Canadian Journal of Infectious Diseases and Medical Microbiology |
| Online Access: | http://dx.doi.org/10.1155/2021/6644570 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832561479076806656 |
|---|---|
| author | Hossein Kasiri Cyrus Mahjub Mohammadreza Mazaeri Fahimeh Naderi-Behdani Aliyeh Bazi Monireh Ghazaeian Sahar Fallah |
| author_facet | Hossein Kasiri Cyrus Mahjub Mohammadreza Mazaeri Fahimeh Naderi-Behdani Aliyeh Bazi Monireh Ghazaeian Sahar Fallah |
| author_sort | Hossein Kasiri |
| collection | DOAJ |
| description | Purpose. Coronavirus disease 2019 (COVID-19) has been associated with a high rate of mortality and morbidity. While a high portion of COVID-19 patients have mild symptoms, a limited number of clinical trials have evaluated the clinical course of this large group of patients. This study was designed to investigate the demographics and clinical characteristics and comorbidity of nonhospitalized COVID-19 patients. Methods. This prospective, observational cohort study was performed on nonhospitalized adult patients (≥18 years) with COVID-19. Pharmacotherapy service was responsible for patients’ assessment for up to 1 month. Demographic characteristics, the onset of symptoms, severity, duration, laboratory data, and hospitalization rate were evaluated by a pharmacist-based monitoring program. Results. From 323 patients who had been referred to the emergency department, 105 individuals were recruited between April 26 and August 2, 2020. Most of the patients were female (66.7%) with a mean age of 39.39 years (SD: ± 15.82). The mean time of the symptom onset was 5.6 days (SD: ±1.79). The majority of patients suffered from fatigue (78.1%), sore throat (67.6%), cough (60%), and myalgia (55.2%). C-reactive protein, white blood cell, lymphocyte, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and hemoglobin levels were recovered significantly during the first two weeks (P<0.001). Hydroxychloroquine, naproxen, diphenhydramine, azithromycin, and vitamin D3 were the most common medications administered (98%, 96%, 94%, 68%, and 57%, respectively). Forty patients were not symptom-free after the one-month follow-up, and 8 patients (7.6%) were required to revisit without the need for hospitalization. Anosmia (18.1%) and fatigue (17.1%) were the most common persisted symptoms. There were no significant differences between symptom-free and symptomatic patients. Conclusion. Mild COVID-19 patients had a wide variety of symptoms and could be symptomatic even one month after the onset of symptoms. The pharmacist-based monitoring system can contribute beneficially to patients through the evaluation of symptoms, reduction of unnecessary visits, and provision of updated information to patients concerning the status of their illness. |
| format | Article |
| id | doaj-art-1cf8702e4ec7459d957998d2736d249e |
| institution | Kabale University |
| issn | 1712-9532 1918-1493 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Infectious Diseases and Medical Microbiology |
| spelling | doaj-art-1cf8702e4ec7459d957998d2736d249e2025-02-03T01:24:54ZengWileyCanadian Journal of Infectious Diseases and Medical Microbiology1712-95321918-14932021-01-01202110.1155/2021/66445706644570A Clinical Monitoring Program of COVID-19 Outpatients: A Prospective Cohort StudyHossein Kasiri0Cyrus Mahjub1Mohammadreza Mazaeri2Fahimeh Naderi-Behdani3Aliyeh Bazi4Monireh Ghazaeian5Sahar Fallah6Department of Clinical Pharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Mazandaran, IranDepartment of Emergency, Ibne Sina Hospital, Mazandaran University of Medical Sciences, Sari, IranDepartment of Emergency, Ibne Sina Hospital, Mazandaran University of Medical Sciences, Sari, IranDepartment of Clinical Pharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Mazandaran, IranDepartment of Clinical Pharmacy, Faculty of Pharmacy, Zabol University of Medical Sciences, Zabol, IranPharmaceutical Research Center, Department of Clinical Pharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, IranDepartment of Biostatistic, Ibne Sina Medical and Educational Center, Mazandaran University of Medical Sciences, Sari, Mazandaran, IranPurpose. Coronavirus disease 2019 (COVID-19) has been associated with a high rate of mortality and morbidity. While a high portion of COVID-19 patients have mild symptoms, a limited number of clinical trials have evaluated the clinical course of this large group of patients. This study was designed to investigate the demographics and clinical characteristics and comorbidity of nonhospitalized COVID-19 patients. Methods. This prospective, observational cohort study was performed on nonhospitalized adult patients (≥18 years) with COVID-19. Pharmacotherapy service was responsible for patients’ assessment for up to 1 month. Demographic characteristics, the onset of symptoms, severity, duration, laboratory data, and hospitalization rate were evaluated by a pharmacist-based monitoring program. Results. From 323 patients who had been referred to the emergency department, 105 individuals were recruited between April 26 and August 2, 2020. Most of the patients were female (66.7%) with a mean age of 39.39 years (SD: ± 15.82). The mean time of the symptom onset was 5.6 days (SD: ±1.79). The majority of patients suffered from fatigue (78.1%), sore throat (67.6%), cough (60%), and myalgia (55.2%). C-reactive protein, white blood cell, lymphocyte, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and hemoglobin levels were recovered significantly during the first two weeks (P<0.001). Hydroxychloroquine, naproxen, diphenhydramine, azithromycin, and vitamin D3 were the most common medications administered (98%, 96%, 94%, 68%, and 57%, respectively). Forty patients were not symptom-free after the one-month follow-up, and 8 patients (7.6%) were required to revisit without the need for hospitalization. Anosmia (18.1%) and fatigue (17.1%) were the most common persisted symptoms. There were no significant differences between symptom-free and symptomatic patients. Conclusion. Mild COVID-19 patients had a wide variety of symptoms and could be symptomatic even one month after the onset of symptoms. The pharmacist-based monitoring system can contribute beneficially to patients through the evaluation of symptoms, reduction of unnecessary visits, and provision of updated information to patients concerning the status of their illness.http://dx.doi.org/10.1155/2021/6644570 |
| spellingShingle | Hossein Kasiri Cyrus Mahjub Mohammadreza Mazaeri Fahimeh Naderi-Behdani Aliyeh Bazi Monireh Ghazaeian Sahar Fallah A Clinical Monitoring Program of COVID-19 Outpatients: A Prospective Cohort Study Canadian Journal of Infectious Diseases and Medical Microbiology |
| title | A Clinical Monitoring Program of COVID-19 Outpatients: A Prospective Cohort Study |
| title_full | A Clinical Monitoring Program of COVID-19 Outpatients: A Prospective Cohort Study |
| title_fullStr | A Clinical Monitoring Program of COVID-19 Outpatients: A Prospective Cohort Study |
| title_full_unstemmed | A Clinical Monitoring Program of COVID-19 Outpatients: A Prospective Cohort Study |
| title_short | A Clinical Monitoring Program of COVID-19 Outpatients: A Prospective Cohort Study |
| title_sort | clinical monitoring program of covid 19 outpatients a prospective cohort study |
| url | http://dx.doi.org/10.1155/2021/6644570 |
| work_keys_str_mv | AT hosseinkasiri aclinicalmonitoringprogramofcovid19outpatientsaprospectivecohortstudy AT cyrusmahjub aclinicalmonitoringprogramofcovid19outpatientsaprospectivecohortstudy AT mohammadrezamazaeri aclinicalmonitoringprogramofcovid19outpatientsaprospectivecohortstudy AT fahimehnaderibehdani aclinicalmonitoringprogramofcovid19outpatientsaprospectivecohortstudy AT aliyehbazi aclinicalmonitoringprogramofcovid19outpatientsaprospectivecohortstudy AT monirehghazaeian aclinicalmonitoringprogramofcovid19outpatientsaprospectivecohortstudy AT saharfallah aclinicalmonitoringprogramofcovid19outpatientsaprospectivecohortstudy AT hosseinkasiri clinicalmonitoringprogramofcovid19outpatientsaprospectivecohortstudy AT cyrusmahjub clinicalmonitoringprogramofcovid19outpatientsaprospectivecohortstudy AT mohammadrezamazaeri clinicalmonitoringprogramofcovid19outpatientsaprospectivecohortstudy AT fahimehnaderibehdani clinicalmonitoringprogramofcovid19outpatientsaprospectivecohortstudy AT aliyehbazi clinicalmonitoringprogramofcovid19outpatientsaprospectivecohortstudy AT monirehghazaeian clinicalmonitoringprogramofcovid19outpatientsaprospectivecohortstudy AT saharfallah clinicalmonitoringprogramofcovid19outpatientsaprospectivecohortstudy |